Ernexa Therapeutics Inc.: Form 10-Q for the period ended Jun 30, 2013
Filed with the SEC on Aug 14, 2013 and accepted by EDGAR at Aug 14, 2013, 17:48 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2013-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2013-04-01 to 2013-06-30 | $5.5m | us-gaap:SalesRevenueNet |
| Revenue | 6 months2013-01-01 to 2013-06-30 | $11.6m | us-gaap:SalesRevenueNet |
| Selling, general and administrative | 3 months2013-04-01 to 2013-06-30 | $4.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2013-01-01 to 2013-06-30 | $8.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2013-04-01 to 2013-06-30 | −$115.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2013-01-01 to 2013-06-30 | −$481.0k | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2013-04-01 to 2013-06-30 | $5.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2013-01-01 to 2013-06-30 | $13.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2013-04-01 to 2013-06-30 | −$99.0k | us-gaap:NetIncomeLoss |
| Net income | 6 months2013-01-01 to 2013-06-30 | −$468.0k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2013-04-01 to 2013-06-30 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2013-01-01 to 2013-06-30 | −$0.01 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2013-01-01 to 2013-06-30 | $346.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2013-01-01 to 2013-06-30 | $285.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2013-06-30 | $2.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2013-06-30 | $3.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2013-06-30 | $11.4m | us-gaap:Assets |
| Current liabilities | At period end2013-06-30 | $2.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2013-06-30 | $4.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2013-06-30 | $7.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001019687-13-003135. Last ingested by Listed: Nov 6, 2026, 17:52 ET. Listed shows no prices and gives no investment advice.